ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Metrics to compare | PROK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPROKPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.0x | −2.7x | −0.5x | |
PEG Ratio | −0.24 | −0.10 | 0.00 | |
Price/Book | −0.6x | 7.1x | 2.6x | |
Price / LTM Sales | 652.5x | 6.7x | 3.1x | |
Upside (Analyst Target) | 197.9% | 79.2% | 57.5% | |
Fair Value Upside | Unlock | 1.1% | 8.6% | Unlock |